Status: Recruiting
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG. Subsequently, the safety and efficacy of the selected IM-101 dose-regimen will be tested in participants with AChR antibody-negative gMG and participants with AChR antibody-positive or AChR antibody-negative oMG.
Participants needed: 96
Trial details
Phase: Phase 1, Phase 2Age: 18-74Biological sex: AllType: InterventionalSponsor: ImmunAbs Inc.Updated: Feb 11, 2026Locations: 25
Eligibility criteria
Able and willing to provide signed informed consent [+6]
Previous exposure to IM-101 [+4]